VACCINEX INC (VCNX)
VCNX moved a median of 0.00% 30 minutes after news, and +1.07% by the close. How VCNX actually reacts to news — the realized, point-in-time move the market made, measured across 185 labeled events over the last three years with zero look-ahead.
VCNX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 152 |
| 30-min | 0.00% | 48% | 164 |
| 60-min | +1.54% | 55% | 169 |
| to close | +1.07% | 55% | 183 |
| Middle 50% of VCNX reactions | -3.15% to +5.60% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 185 |
Half of all VACCINEX INC news events land between -3.15% and +5.60% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VCNX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VCNX's baseline. Nothing else.
Recent VCNX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study | Press release | GlobeNewswire | +0.00% | +15.00% | |
| Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026 | Press release | GlobeNewswire | +0.00% | +15.18% | |
| Vaccinex Reports 2025 Annual Financial Results | Press release | GlobeNewswire | — | — | |
| Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease | Press release | GlobeNewswire | +0.00% | -22.82% | |
| Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting | Press release | GlobeNewswire | +0.00% | +45.88% | |
| Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | Press release | GlobeNewswire | +0.00% | -4.00% | |
| Form 10-K VACCINEX, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.00% | |
| Form NT 10-K VACCINEX, INC. For: Mar 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | +31.41% | |
| Form 15-12G VACCINEX, INC. | SEC filing · Form 15-12G | SEC EDGAR | -13.06% | -1.61% | |
| Form EFFECT VACCINEX, INC. | SEC filing · Form EFFECT | SEC EDGAR | +131.06% | +84.85% | |
| Form POS AM VACCINEX, INC. | SEC filing · Form POS | SEC EDGAR | -11.75% | +61.74% | |
| Form S-8 POS VACCINEX, INC. | SEC filing · Form S-8 | SEC EDGAR | -11.75% | +61.74% | |
| Form 8-K VACCINEX, INC. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 25 VACCINEX, INC. | SEC filing · Form 25 | SEC EDGAR | +0.00% | -0.11% | |
| Form 8-K VACCINEX, INC. For: Mar 07 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | -1.19% | |
| Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market | Press release | GlobeNewswire | +0.75% | -1.19% | |
| Form 8-K VACCINEX, INC. For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | -8.00% | -19.43% | |
| Vaccinex Announces Receipt of Delisting Notification from Nasdaq | Press release | GlobeNewswire | -13.33% | -27.32% | |
| Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | -4.01% | |
| Form 10-Q VACCINEX, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -13.43% | |
| Form 8-K VACCINEX, INC. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -13.43% | |
| Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC | Press release | GlobeNewswire | -1.51% | +0.00% | |
| Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting | Press release | GlobeNewswire | -0.00% | +3.13% | |
| Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain | Press release | GlobeNewswire | +4.90% | -31.62% | |
| Form EFFECT VACCINEX, INC. | SEC filing · Form EFFECT | SEC EDGAR | -0.90% | +0.90% | |
| Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024 | Press release | GlobeNewswire | -0.19% | +21.94% | |
| Form S-3 VACCINEX, INC. | SEC filing · Form S-3 | SEC EDGAR | -2.72% | -1.95% | |
| Form 8-K VACCINEX, INC. For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +5.56% | +11.11% | |
| Form D VACCINEX, INC. | SEC filing · Form D | SEC EDGAR | — | +0.59% | |
| Form 8-K VACCINEX, INC. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -11.99% | |
| Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds | Press release | GlobeNewswire | -0.56% | -4.44% | |
| Form 8-K VACCINEX, INC. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +2.73% | +4.18% | |
| Form 8-K VACCINEX, INC. For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.14% | |
| Form 10-Q VACCINEX, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.51% | -7.17% | |
| Form 8-K VACCINEX, INC. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +11.35% | |
| Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership | Press release | GlobeNewswire | +0.00% | +11.35% | |
| Form 8-K VACCINEX, INC. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -8.85% | -31.08% | |
| Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease | Press release | GlobeNewswire | -8.85% | -31.08% | |
| Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024 | Press release | GlobeNewswire | +10.26% | +4.98% | |
| Form EFFECT VACCINEX, INC. | SEC filing · Form EFFECT | SEC EDGAR | — | -2.88% | |
| Form S-3 VACCINEX, INC. | SEC filing · Form S-3 | SEC EDGAR | — | +1.56% | |
| Form 8-K VACCINEX, INC. For: Jun 06 | SEC filing · Form 8-K | SEC EDGAR | +3.86% | -1.15% | |
| Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease | Press release | GlobeNewswire | +3.86% | -1.15% | |
| Form 10-Q VACCINEX, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -1.13% | |
| Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | -1.13% | |
| Form EFFECT VACCINEX, INC. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -5.74% | |
| Form S-8 VACCINEX, INC. | SEC filing · Form S-8 | SEC EDGAR | — | +11.87% | |
| Form 8-K VACCINEX, INC. For: May 09 | SEC filing · Form 8-K | SEC EDGAR | +9.80% | +2.50% | |
| Form S-3/A VACCINEX, INC. | SEC filing · Form S-3 | SEC EDGAR | — | +0.00% | |
| Form S-3 VACCINEX, INC. | SEC filing · Form S-3 | SEC EDGAR | — | -0.34% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VCNX section they belong to.
Where else VCNX is measured.
VCNX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CHOOM HLDGS INC (CHOOF) | 185 | -0.11% | 48% |
| Kamada Ltd. - Ordinary Shares (KMDA) | 185 | 0.00% | 44% |
| CONVATEC GRP PLC UNSP/ADR (CNVVY) | 184 | 0.00% | 37% |
| Surmodics, Inc. (SRDX) | 184 | -0.02% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is VACCINEX INC's median reaction calculated?
Every labeled VCNX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 185 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of VCNX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VCNX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.